Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:33 PM
Ignite Modification Date:
2025-12-24 @ 3:33 PM
NCT ID:
NCT07078292
Eligibility Criteria:
Inclusion Criteria:
* Age ≥ 18 years old, male or female not limited
* Non resectable HCC patients diagnosed by tissue/cytology or imaging that meets the diagnostic criteria for HCC
* There must be at least one measurable lesion (RECIST 1.1)
* Use immunotherapy combination therapy as first-line treatment, including atezolizumab+bevacizumab, sintilizumab+bevacizumab analogs, carrelizumab+apatinib, lenvatinib+tirelizumab or sintilizumab, with or without local treatment (including but not limited to TACE, HAIC)
* Have not received systematic anti-tumor treatment in the past
* Child Pugh 5-7 points
* ECOG PS 0-1 points
* Prospective cohort requires patients to have at least one imaging tumor evaluation since baseline;
Exclusion Criteria:
* Lack of baseline data and post-treatment imaging data
* With other malignant tumors
* Merge severe cardiovascular diseases and uncontrollable infections
* Existence of any active autoimmune disease or history of autoimmune disease Expected survival period\<3 months
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07078292
Study Brief:
Protocol Section:
NCT07078292